GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. (Q44066995)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

title

GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

G protein-coupled receptor

30 August 2019

main subject

glycobiology

0 references

0 references

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

author name string

R L Dobbins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

S P Shearn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

R L Byerly

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

F F Gao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

K M Mahar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

A Napolitano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

A-C Le Monnier de Gouville

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

publication date

12 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

30 August 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

30 August 2019

page(s)

1013-1021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23701262 AND SRC:MED&resulttype=core&format=json

Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR).

30 August 2019

cites work

1 reference

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM.

21 January 2018

1 reference

Cellular mechanisms of insulin resistance

21 January 2018

1 reference

Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes

21 January 2018

1 reference

Effect of fatty acids on glucose production and utilization in man

21 January 2018

1 reference

Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes

21 January 2018

1 reference

Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients

21 January 2018

1 reference

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects

21 January 2018

1 reference

Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia

21 January 2018

1 reference

The nicotinic acid receptor--a new mechanism for an old drug

21 January 2018

1 reference

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

HM74a agonists: will they be the new generation of nicotinic acid?

21 January 2018

1 reference

Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia

21 January 2018

1 reference

The metabolic syndrome: practical guide to origins and treatment: Part I.

21 January 2018

1 reference

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

21 January 2018

1 reference

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

Use and abuse of HOMA modeling

21 January 2018

1 reference

Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans.

21 January 2018

1 reference

Glycerol production and utilization measured using stable isotopes

21 January 2018

1 reference

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes

21 January 2018

1 reference

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes

21 January 2018

1 reference

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

Acipimox enhances spontaneous growth hormone secretion in obese women

21 January 2018

1 reference